News Amgen Inc.

Equities

AMGN

US0311621009

Market Closed - Nasdaq Other stock markets 04:00:01 2024-05-31 pm EDT			5-day change	1st Jan Change
305.8 ^USD	+1.59%		-0.01%	+6.17%

May. 28	US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	RE
May. 28	Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amgen : 2024 Annual Meeting of Stockholders Presentation	May. 31	PU
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	May. 28	RE
Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval	May. 28	DJ
Weight-loss drug forecasts jump to $150 billion as supply grows	May. 28	RE
Supreme Court Holds Invalid Cholesterol Drug Patent That Covered Millions Of Undisclosed Antibodies	May. 27	AQ
Amgen : An Underrecognized Risk Factor for Heart Disease	May. 23	PU
Improving treatment responses to solid tumours with trispecific TCEs	May. 23	AQ
Amgen : From the Office to the Lab, Amgen Uses AI Tools to Unlock Innovation	May. 22	PU
Sandoz: Marketing authorization for Wyost and Jubbonti in the EU	May. 22	CF
Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test	May. 22	MT
Amgen : Actress and Producer Gina Torres Urges Hispanic Americans to Prioritize Cholesterol Care	May. 21	PU
Amgen : At Milken Global Conference, Bradway Calls for Protecting U.S. Policy Ecosystem That Fosters Innovation	May. 20	PU
Driving Long-Term Growth: IMDELLTRA™ Approval and Information Update Presentation	May. 20	PU
Transcript : Amgen Inc. - Special Call	May. 20
Astrazeneca - New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease	May. 20	AQ
AMGEN - NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE TO HELP PATIENTS LIVING WITH COPD	May. 20	AQ
HSBC Adjusts Price Target on Amgen to $356 From $322	May. 20	MT
Amgen and AstraZeneca's Lung Disease Drug Study Reports Mixed Results	May. 20	MT
Amgen And Sandoz Settle Denosumab BPCIA Litigation	May. 20	AQ
Amgen Announces the Results of the Phase 2a COURSE Trial Evaluating Tezspire® (Tezepelumab-Ekko) in People with Moderate to Very Severe Chronic Obstructive Pulmonary Disease	May. 19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Amgen Inc.

Equities

AMGN

US0311621009

Summary

Filters